Ensysce biosciences regains full compliance with nasdaq

San diego, california / accesswire / december 23, 2024 / ensysce biosciences, inc. (nasdaq:ensc) ("ensysce" or "company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on december 20, 2024, it received notice from the nasdaq stock market llc ("nasdaq") that the company has demonstrated compliance with the minimum bid price requirement in listing rule 5550(a)(2). ensysce had previously regained compliance with the stockholders' equity requirement in listing rule 5550(b)(1).
NDAQ Ratings Summary
NDAQ Quant Ranking